Drug maker Eli Lilly announces withdrawal from Russia
[ad_1]
The American pharmaceutical company Eli Lilly has transferred the rights to import its drugs to Russia to the local representative office of the Swiss company Swixx Biopharma. This was reported to Vedomosti by a representative of the Eli Lilly office in the Russian Federation.
According to him, Swixx Biopharma will sell drugs to the American company and ensure that the company fulfills its obligations for local production. The agreement between the parties will allow the continued supply of Eli Lilly’s vital medicines to Russia for the treatment of patients with diabetes mellitus, oncological, autoimmune and neurological diseases, he concluded.
In March 2022, after the start of the CBO, Eli Lilly stopped supplying medicines to Russia that were not included in the list of vital and essential drugs. In particular, drugs for the treatment of erectile dysfunction Cialis (but it has analogues).
In May last year, the American Bristol-Myers Squibb transferred its Russian business to a subsidiary of Swixx Biopharma, Swix Healthcare LLC, in a similar way.
Eli Lilly has been importing medicines for Russian patients since 1989. According to the results of last year, the company ranked 18th in the TOP-20 manufacturers supplying medicines to hospitals, with a revenue of 7.3 billion rubles. Compared to the previous year, this figure fell by 23.9%, according to data from the analytical company DSM Group.
The representative of Swixx Biopharma in Russia did not respond to a request from Vedomosti.
[ad_2]
Source link
